10.00
+0.17(+1.73%)
Currency In USD
Address
8335 Sunset Boulevard
Calabasas, CA 90069
United States of America
Phone
310-663-7831
Website
Sector
Healthcare
Industry
Biotechnology
Employees
8
First IPO Date
March 26, 2025
| Name | Title | Pay | Year Born |
| Amir Farrokh Heshmatpour | President, Chief Executive Officer, Executive Chairman & Secretary | 0 | 1967 |
| Keithly A. Garnett | Chief Financial Officer | 179,000 | 1975 |
| Thomas C. Chen | Founder, Chief Medical Officer, Chief Scientific Officer & Vice Chairman | 212,000 | 1965 |
| Josh Neman-Ebrahim | Chief Clinical Officer | 0 | N/A |
Neonc Technologies Holdings, Inc. develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.